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Purpose
The purpose of this study was to investigate the impact of contrast enhanced pancreatic
magnetic resonance imaging (MRI) in resectability and prognosis evaluation after staging
computed tomography (CT) in patients with pancreatic ductal adenocarcinoma (PDA). 
Materials and Methods
From January 2005 to December 2012, 298 patients were diagnosed to have potentially
resectable stage PDA on CT. Patients were divided into CT+MR (patients underwent both CT
and MRI; n=216) and CT only groups (n=82). Changes in resectability staging in the CT+MR
group were evaluated. The overall survival was compared between the two groups. The 
recurrence-free survival and median time to liver metastasis after curative surgery were com-
pared between the two groups.  
Results
Staging was changed from resectable on CT to unresectable state on MRI in 14.4% of (31
of 216 patients) patients of the CT+MR group. The overall survival and recurrence-free sur-
vival rates were not significantly different between the two groups (p=0.162 and p=0.721,
respectively). The median time to liver metastases after curative surgery in the CT+MR group
(9.9 months) was significantly longer than that in the CT group (4.2 months) (p=0.011).  
Conclusion
Additional MRI resulted in changes of resectability and treatment modifications in a signif-
icant proportion of patients who have potentially resectable state at CT and in prolonged
time to liver metastases in patients after curative surgery. Additional MRI to standard staging
CT can be recommended for surgical candidates of PDA.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) is one of the
greatest challenging tumors among malignant neoplasms 
because of its aggressive course with persistent high cancer
related mortality rate over the last few decades [1]. The 
5-year survival rate in patients with pancreatic cancer is less
than 5 to 6% worldwide [2]. Surgical resection is the only 
potential for curative treatment and can prolong survival,
but only 15% to 25% of patients constitute the surgical can-
didates at the time of diagnosis [1,3,4]. Even after curative
surgery, the actuarial 5-year overall survival has been 
reported to be only 18% to 25% in the most experienced of
hands and in-hospital mortality was reported from 4.6% to
7.8% [1,5]. These facts emphasize the need to avoid futile sur-
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gery to minimize perioperative mortality and to improve 
patients’ quality of life and long-term survival.
To date, computed tomography (CT) has become a widely
accepted imaging modality as the standard for patients with
clinical suspicion of pancreatic cancer [3,6-8]. However, sev-
eral studies have shown that CT as a sole imaging modality
is insufficient in the determination of surgical unresectability
of PDA [9-11]. A previous study with meta-analysis reported
that the mean probability of unresectable disease after CT
scan across studies was approximately 61% in patients with
potentially resectable pancreatic and periampullary cancer
[9]. With recent advances in magnetic resonance imaging
(MRI), MRI has been widely used to evaluate hepatopancre-
aticobiliary disease. However, it is not clear as to which pan-
creatic cancer patients should undergo MRI in addition to
the standard pancreatic CT. National Comprehensive Cancer
Network (NCCN) clinical practice guidelines ver. 2. 2015
proposed that contrast enhanced MRI with magnetic reso-
nane (MR) cholangiopancreatography (MRCP) can be con-
sidered to further evaluate patients in whom no mass was
detected on pancreatic protocol CT or those with CT-inde-
terminate liver lesions [12]. This recommendation might
have been based on the fact that MRI is more sensitive in 
detecting small masses or minimal ductal changes in the pan-
creas and small lesions in the liver owing to its high tissue
contrast [7]. However, there is no existing clear guideline
whether the MRI in the surgical candidates with visible pan-
creatic mass on CT is additionally needed or not. Consider-
ing the high perioperative mortality and low survival after
curative surgery in patients with PDA, the role of imaging
in PDA should be further emphasized with regard to accu-
rate staging for resectability to minimize the morbidity from
unnecessary laparotomies or major surgeries, in addition to
maximize the survival benefit in patients with curative treat-
ment. To the best of our knowledge, there has been no pre-
vious study demonstrating the incremental value of the
additional MRI performed after CT, especially in predicting
the resectability and the clinical outcome.
In this study, we aimed to investigate the clinical impact
of MRI on resectability evaluation and the effect on the over-
all and recurrence-free survival in patients with standard CT
initially interpreted to have potentially resectable PDA.
Materials and Methods
1. Patients
We searched the electrical medical records at out institu-
tion to identify the study patients. The eligibility criteria for
the main investigation included the following: (1) patients
who were histopathologically diagnosed with PDA between
January 2005 and December 2012; (2) patients identified to
have potentially resectable PDA on CT. One thousand eight
hundred fifty-two consecutive patients were newly diag-
nosed with PDA during this period. All of them underwent
CT imaging for work-up of PDA. Our standardized clinical
reports on staging CT for PDA, which were made by experi-
enced board-certified abdominal radiologists, were used to
identify relevant patients. Two radiologists in consensus 
reviewed the imaging findings of the baseline CT with 
reports, and subsequently classified PDA patients into four
categories (resectable, borderline resectable, unresectable,
and indeterminate state) based on the 2015 NCCN practice
guidelines, in order to determine the surgical resectability
[12]. The potentially resectable PDA in our study included
resectable, borderline resectable, and indeterminate state. 
Patients were excluded if they had the following: (1) incom-
plete clinical or radiological data (n=566), (2) unresectable
state on CT imaging review (n=946), (3) non-contrast CT or
MRI (n=22), and (4) age more than 80 years (n=20). Hence, a
total of 298 patients (165 men, 133 women; mean age, 62
years; range, 27 to 80 years) were included in the main study
population with potentially resectable PDA on CT. Of these,
82 patients only underwent CT (CT group) and 216 patients
underwent MRI within 4 weeks after CT acquisition (CT+MR
group). The recommendation regarding the subsequent MRI
was made in consensus at multidisciplinary pancreatobiliary
meeting, but the final decision was left to the attending
physician’s judgment. Clinical information including patient
demographics, laboratory data, treatment methods, and
histopathology reports were reviewed using electronic med-
ical records. Of the 298 patients, 161 (54%) who received cur-
ative surgical resection were included for subgroup analysis
to evaluate the recurrence-free survival and time to liver
metastasis after surgery. The flowchart of the study popula-
tion is presented in Fig. 1.
2. CT imaging
All patients underwent CT examinations with either a 
16-channel or 64-channel scanner (Sensation 16 or Sensation
64, Siemens, Erlangen, Germany; Brilliance 64, Philips
Healthcare, Cleveland, OH). After obtaining non-contrast CT
images, contrast-enhanced pancreatic CT were performed
with intravenous administration of nonionic contrast medium
(Ultravist 300, Schering, Berlin, Germany). Pancreatic and
portal venous phase imaging was obtained by adding 18 sec-
onds to the time of peak abdominal aortic enhancement cal-
culated at the hepatic hilum, and 18 seconds to the end of the
pancreatic phase, respectively. In 38 patients, only the portal
venous phase CT was obtained. The scanning parameters
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were as follows: beam collimation, 0.75 and 0.625 mm; slice
thickness, 5 and 3 mm; reconstruction interval, 5 and 3 mm;
rotation time, 0.5 seconds; effective tube current-time charge,
150-250 mAs; 120 kVp for the 16- and 64-channel scanner, 
respectively.
3. Magnetic resonance imaging
MRI was performed by using a 1.5-T (Intera Achieva,
Philips Medical Systems, Best, Netherlands) or 3.0-T scanner
(Magnetom Trio Tim, Siemens Medical Solutions, Erlangen,
Germany) using 4- or 16-channel torso-array coil. All patients
underwent baseline non-contrast and post-contrast dynamic
MRI. Both single-section and navigator-triggered MRCP 
imaging were performed. Dynamic T1-weighted imaging
was obtained after administering one of the two contrast 
materials (Primovist, Bayer Schering Pharma, Berlin, Ger-
many; Dotarem, Guerbet, France): a bolus injection of 0.1
mL/kg gadoxetic acid (n=186) at a rate of 1.0 mL/sec or 0.2
mL/kg gadoterate meglumine (n=30) at a rate of 2.0 mL/sec,
followed by a 20 mL saline flush using a power injector. The
peak time of the time-density curve to determine image 
acquisition timing was achieved using a test-bolus technique
in which 1 mL of gadoxetic acid or of gadoterate meglumine
was injected with a saline flush. The arterial phase began 
2 or 3 seconds after the peak aortic enhancement was deter-
mined. Subsequent portal (50 seconds) and transitional 
(3 minutes) phase images were obtained. Additional hepa-
tobiliary phase (20 minutes) images were obtained when 
gadoxetic acid (hepatocyte-specific agent) were used. Diffu-
Excluded due to incomplete clinical or radiologic data (n=566)
Patients were diagnosed as PDA by CT between January 2005 
and December 2012 (Source population) (n=1,852)
Patients were categorized by 2015 NCCN practice guidelines (n=1,286)
Patients were identified as potentially resectable states by CT (n=340)
Patients with potentially resectable PDA at CT (Study population) (n=298)
Had CT
CT group (n=82)
Had CT and MRI
CT+MR group (n=216)
Surgical resection (n=49)
No surgery (n=33)
Potentially resectable PDA (n=185)
  Surgical resection (n=111)
  No surgery (n=74)
Excluded with unresectable state at CT (n=946)
Excluded (n=42)
  Age > 80 yr (n=20)
  Noncontrast MR imaging (n=21)
  Noncontrast CT scan (n=1)
Unresectable PDA (n=31)
  Surgical resection (n=1)
  No surgery (n=30)
Fig. 1. Flow diagram of study population. PDA, pancreas ductal adenocarcinoma; CT, computed tomography; NCCN, 
National Comprehensive Cancer Network; MRI, magnetic resonance imaging. 
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sion-weighted imaging was obtained at b values of 0, 50, 400,
and 800 sec/mm2. In our institution, both hepatocyte-specific
contrast agent (gadoxetic acid) and diffusion weighted 
imaging (DWI) were introduced on February 2008. There-
after, they became the routine protocol. Detailed MR param-
eters are provided in S1 Table.
4. Assessment of resectability
Two, board-certified abdominal radiologists (with 6 and
11 years of experience in abdominal imaging, respectively)
in consensus retrospectively reviewed the all baseline CT 
images (n=298 patients) with reference to prospectively 
interpreted reports at Picture Archiving Communication Sys-
tem. They classified the patients into three categories (resec-
table, borderline resectable, and unresectable states) based
on the 2015 NCCN, as defined in S2 Table. Patients who did
not belong to above the three NCCN categories (i.e., patients
with hepatic lesions considered too small to characterize or
lesions which are difficult to categorize between benign or
malignant lesions in any organ) were classified as an inde-
terminate state. After four weeks, the same radiologists 
reviewed and classified the MRI (n=216 patients) in the same
manner as CT. While reviewing the MRI, they simultane-
ously referred to the CT imaging findings as in routine clin-
ical practice. The radiologists were informed that all patients
had PDA, but they were blinded to all other things, including
clinical and laboratory findings and the histo-pathological
stage.
5. Outcomes and follow-up evaluation
The primary outcome of this study was change in surgical
resectability after additional MRI in patients with potentially
resectable PDA on CT. Secondary outcomes included overall
survival rates for all patients, and recurrence-free survival
rates and time to liver metastases for patients receiving cur-
ative surgical treatment, between the CT only and CT+MR
groups. The index date was defined as the date on which the
patient underwent baseline CT for the diagnosis of PDA. 
Patients were followed up from the index date till death or
the last follow-up date. Each patient’s overall and recurrence-
free survival was calculated from the index date till death,
date of last follow-up evaluation, or confirmation of recur-
rence. To substantiate the completeness of the follow-up
data, information about vital status was obtained from the
National Population Registry of the Korea National Statisti-
cal Office using unique personal identification numbers. Cur-
ative-intent treatments were defined as curative surgical
resection regardless of neoadjuvant concurrent chemoradio-
therapy. The routine follow-up protocol included serum car-
bohydrate antigen (CA) 19-9 and contrast-enhanced CT.
Recurrence of PDA was defined to have occurred when local
recurrence or distant metastatic lesions were first evident in
the medical record, based on a combination of follow-up CT
imaging, CA 19-9 level, histological confirmation, or physical
examination. Time to liver metastases was calculated from
the date of curative surgery to the initial presentation date of
liver metastases on follow-up CT among patients receiving
curative surgical treatment. Subgroup analysis was per-
formed for patients in the CT+MR group. They were divided
into persistently potentially resectable and unresectable
states based on the CT+MR findings, and the overall and 
recurrent-free survival was compared between the two
groups.
6. Statistical analysis
Clinical characteristics of all patients were compared 
between the CT only and CT+MR groups using the Student
t test for continuous variables and the chi-square test for cat-
egorical variables. Kaplan-Meier survival analysis and Cox
proportional hazards regression were used to assess the 
impact of additional MRI on overall survival and recurrence-
free survival. Time to liver metastases for the CT and CT+MR
groups were compared by using Mann-Whitney U test.
Statistical analyses were performed by our statistician
using the R software ver. 3.3.1. (R Foundation for Statistical
Computing, Vienna, Austria). All reported p-values were
two sided with a significant level of less than 0.05.
7. Ethical statement
This historical cohort study was approved by the institu-
tional review board of Severance Hospital (IRB No. 2016-
1611) that is a tertiary referral center with high volume of
pancreatic cancer, and the requirement for informed consent
from patients was waived.
Results
1. Patient characteristics
Clinical characteristics of the patients are summarized in
Table 1. The proportion of patients receiving neoadjuvant
concurrent chemoradiotherapy before surgical resection was
significantly higher in the CT group (53.1%) than in the
CT+MR group (30.4%) (p=0.006). The other baseline charac-
teristics of patients in the CT and CT+MR groups were not
significantly different. The proportion of patients undergo-
ing additional MRI was 72.4% (142 of 196 patients) for the 
VOLUME 51 NUMBER 1 JANUARY 2019  27
Hye Jin Kim, Role of MRI in Pancreas Ductal Adenocarcinoma
resectable state, 66.2% (49 of 74 patients) for the borderline
resectable state, and 89.3% (25 of 28 patients) for the indeter-
minate state at CT classification, without statistical difference
(p=0.067).
2. Changes in surgical resectability and treatment of PDA
after additional MR imaging
Of the 216 patients in the CT+MR group, a total of 31 
patients (14.4%) who had potentially resectable states on CT
were changed to have unresectable state on additional MRI
(Table 2). Liver metastases (n=16), major vascular invasion
(n=13), enlarged para-aortic lymph node (n=1), and peri-
toneal seeding (n=1) were additionally found by MRI. Of the
16 patients with liver metastases diagnosed on MRI, nine 
patients had negative-liver-on-CT (4.7%, 9 of 191 resectable
or borderline resectable group on CT) (Fig. 2) and seven 
patients had diminutive indeterminate hepatic lesions on CT
(35%, 7 of 20). Of the 13 patients with unresectable state due
to major vascular invasion on MRI, three patients had no
Table 1.  Characteristics of the full cohort
Characteristic Total (n=298) CT (n=82) CT+MR (n=216) p-value
Age (yr) 62.19±10.02 61.94±10.64 62.28±9.79 0.795
Male sex 164 (55) 48 (58.5) 116 (53.7) 0.454
Associated factor
Smoking 79 (26.5) 20 (24.4) 59 (27.3) 0.610
Alcohol 80 (26.8) 21 (25.6) 59 (27.3) 0.767
Diabetes 110 (36.9) 35 (42.7) 75 (34.7) 0.204
CA19-9 level (U/mL) 213 (43.1-87.9) 271 (63.1-921) 183 (38.5-871) 0.275
CT phases
Single 38 (12.8) 8 (9.8) 30 (13.9) 0.370
Dual 260 (87.2) 74 (90.2) 186 (86.1)
Curative treatment 161 (54.0) 49 (59.8) 112 (51.9) 0.221
Surgical resection without neoadjuvant CCRT 101 (62.7) 23 (46.9) 78 (69.6) 0.006
Surgical resection after neoadjuvant CCRT 60 (37.3) 26 (53.1) 34 (30.4)
Resected margin
R0 144 (89.4) 42 (85.7) 102 (91.1) 0.309
R1 17 (10.6) 7 (14.3) 10 (8.9)
Follow-up period (yr) 1.49 (0.85-3.20) 1.59 (0.91-4.57) 1.43 (0.82-2.79) 0.193
Values are presented as mean±SD, number (%), or median (IQR). Values were evaluated by chi-square test for categorical
variables and by independent t test for continuous variables. CT, computed tomography; CT+MR, patients underwent both
CT and magnetic resonance imaging; CA19-9, carbohydrate antigen 19-9; CCRT, concurrent chemoradiotherapy; R0, negative
resection margin; R1, positive microscopic resection margin.
MR assessment of surgical resectability
CT assessment Sub-total Borderline Changes inResectable resectable Indeterminate Unresectable surgicalresectability
Resectable 142 (65.7) 123 ( 8 ( 0 ( 11 (7.7) 11 (7.7)
Borderline resectable 49 (22.7) 4 ( 33 ( 0 ( 12 (24.5) 12 (24.5)
Indeterminate 25 (11.6) 8 ( 6 ( 3 ( 8 (32.0) 8 (32.0)
Total 216 (100) 135 (62.5) 47 (21.8) 3 (1.4) 31 (14.4) 31 (14.4)
Table 2. Changes in the surgical resectability of pancreatic ductal adenocarcinoma by MRI at CT+MR group
Values are presented as number (%). MRI, magnetic resonance imaging; CT+MR, patients underwent both computed 
tomography and magnetic resonance imaging; CT, computed tomography.
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major vessel invasion on CT (1.4%, 2 of 142 resectable group
and 4%, 1 of 25 indeterminate group on CT) and 10 patients
had borderline vascular invasion on CT (20.4%, 10 of 49 bor-
derline group on CT). Two of five patients with indetermi-
nate extrahepatic lesions (omental haziness and preaortic
lymph node) other than indeterminate hepatic lesions on CT
were changed to surgically resectable state after MRI. After
analysis of MRI, 185 patients in CT+MR group were 
remained as persistently potentially resectable. There was no
significant difference in the overall proportion of the patients
who received curative surgical treatment between the CT
only (49 of 82, 59.8%) and the persistently potentially resec-
table CT+MR groups (111/185, 60%) (p=0.970). Thirty of 31
patients reclassified into the unresectable state after MRI did
not receive curative surgical treatment (96.8%).
3. Overall and recurrence-free survival
The median follow-up period was 1.6 years for the CT
group and 1.4 years for the CT+MR group without signifi-
cant difference between the two groups (p=0.193). The 5-year
overall survival rates of the CT only and CT+MR groups
were 24.1% and 17.2%, respectively, without statistical dif-
ference (p=0.162) (S3A Fig.).
Within the CT+MR group, the 5-year overall survival rates
between the potentially resectable (19.2%) and unresectable
(4.8%) subgroups were significantly different (p < 0.001)
(hazard ratio [HR], 2.27; 95% confidence interval [CI], 1.53 to
3.37; p < 0.001) (Fig. 3). The curative surgical treatment per-
formed in PDA patients was significantly associated with a
lower risk of overall patient mortality (HR, 0.39; 95% CI, 0.29
to 0.52; p < 0.001) (Table 3).
A total of 161 patients (54%) received curative surgical 
resection with 112 patients in the CT+MR group and 49 
patients in the CT group. Five-year recurrence-free survival
rates were 29.8% and 29.7%, respectively, without statistical
difference (p=0.721) (S3B Fig.). However, the median time to
Fig. 2.  Computed tomography (CT) and magnetic resonance (MR) images obtained in a 65-year-old man with pancreas
ductal adenocarcinoma. (A, B) Portal phase CT image demonstrates no focal liver lesion (A). This patient was classified into
surgically resectable state at CT (pancreas cancer not seen at this image). However, additional gadoxetic acid-enhanced MR
image shows multiple subcentimeter low signal intensity nodules indicating hepatic metastases at hepatobiliary phase 
(arrowheads) (B). Finally, this patient was reclassified into unresectable state after MR imaging.
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Fig. 3.  Overall survival of patients belonged to the poten-
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both computed tomography and magnetic resonance 
imaging) and the unresectable (UR) CT+MR group.
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liver metastases developed after curative surgery was 4.2
months in the CT group and 9.9 months in the CT+MR group
with significant difference between the two groups (p=0.011),
although the number of liver metastases confronted during
their whole follow-up period was not very different (44 of
112 patients [39.3%] in the CT+MR group and 20 of 49 
patients [40.8%] in the CT group) (Fig. 4).
Discussion
Our study results demonstrated that additional MRI 
resulted in changes of surgical resectability and treatment
modifications in a significant proportion of patients who
have potentially resectable states at CT, owing to the addi-
tional detection of liver metastases (n=16), major vascular 
invasion (n=13), enlarged para-aortic lymph node (n=1), and
peritoneal seeding (n=1).
The most common site of metastasis in pancreatic cancer
is the liver [13,14]. A lot of studies have reported the superior
Variable
Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Overall mortalitya)
Age 1.021 1.007-1.035 0.004 1.014 1.000-1.029 0.046
Male sex 1.076 0.835-1.386 0.573 - - -
Smoking 1.066 0.805-1.411 0.655 - - -
Alcohol 0.928 0.700-1.231 0.606 - - -
Diabetes 1.205 0.931-1.561 0.157 - - -
CA 19-9 level 1.010 1.006-1.014 < 0.001 1.007 1.003-1.011 0.001
Curative treatment 0.345 0.266-0.447 < 0.001 0.388 0.292-0.515 < 0.001
CT+MR vs. CT 1.225 0.920-1.632 0.164 - - -
Unresectable at MRI 2.272 1.533-3.367 < 0.001 1.500 0.981-2.294 0.062
PDA recurrenceb)
Age 1.001 0.981-1.022 0.891 - - -
Male sex 1.417 0.965-2.079 0.075 - - -
Smoking 1.034 0.686-1.559 0.873 - - -
Alcohol 0.942 0.627-1.414 0.771 - - -
Diabetes 1.227 0.840-1.791 0.290 - - -
CA 19-9 level 1.004 0.993-1.016 0.448 - - -
Curative treatment 1.292 0.876-1.907 0.197 - - -
CT+MR vs. CT 0.947 0.636-1.412 0.791 - - -
Table 3. Predictive factors of overall patient mortality and PDA recurrence in the full cohort
The Cox proportional hazards model was used for all analyses. PDA, pancreas ductal adenocarcinoma; HR, hazard ratio;
CI, confidence interval; CA 19-9, carbohydrate antigen 19-9; CT+MR, patients underwent both computed tomography and
magnetic resonance imaging; CT, computed tomography; MRI, magnetic resonance imaging. a)Total number of patients, 298;
number of events, 245, b)Total number of patients who received curative surgical treatment, 161; number of events, 112.  
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Fig. 4.  Time to liver metastases in the computed tomog-
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CT and magnetic resonance imaging) groups of patients
who received curative surgical treatment.
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sensitivity of MRI in detecting and characterizing liver 
lesions compared to CT, even though most of them were per-
formed in patients with colorectal cancer liver metastasis 
[15-18]. However, a recent large scale study on colorectal
liver metastasis showed that there was no additional yield
for MRI (0%, 0/94) in the negative-liver-on-CT patients and
only 3% (3/96) additional yield in patients with diminutive
indeterminate hepatic lesions on CT, suggesting that MRI
might provide little clinical benefit in addition to CT, in spite
of the superior diagnostic accuracy of MRI than CT in these
patients [19]. In our study on PDA, however, MRI identified
occult liver metastases in 4.7 % (9 of 191) of patients with neg-
ative-liver-on-CT and 35% (7 of 20) of patients with diminu-
tive indeterminate hepatic lesions on CT. A recently publi-
shed study reported that 23.2% (16 of 69) of PDA patients
with negative-liver-on-CT showed occult liver metastases on
MRI [20]. These results suggest that MRI might provide 
additional clinical benefit for detecting synchronous liver
metastasis in patients diagnosed with resectable PDA inter-
preted by CT (negative-liver-on-CT). It may be further sup-
ported by our results that showed a significant longer time
of onset for hepatic metastases after curative surgery in 
patients of the CT+MR group (9.9 months) than in those of
the CT only group (4.2 months).
Unlike liver metastases from colorectal cancer, there have
been few published papers comparing the diagnostic per-
formance of CT and MRI on liver metastases from PDA. A
recent study reported the significantly higher sensitivity of
gadoxetic acid-enhanced MRI (85%) compared to CT (69%)
for detection of liver metastases from PDA, due to higher 
lesion-to-liver contrast on hepatocyte phase MR image [18].
A prospective pilot study with a small number of patients
with liver metastases from PDA showed significantly higher
sensitivity (86.7%) and specificity (97.5%) for MRI with DWI
than multi-detector CT (MDCT) (53.3% and 77.8%, respec-
tively) [21]. In our study, majority of patients (86%, 186/216)
underwent MRI using gadoxetic acid-enhanced MRI with
DWI and these state-of-the-art MRI may be one of the rea-
sons for the additional detection of liver metastases, resulting
in changes in the treatment plan and longer time to liver
metastases after surgery in the CT+MR group. Also, this pilot
study showed that most liver metastases in patients with 
potentially resectable PDA on CT were small in size (mean
diameter, 7.8±3.1 mm; range 3 to 15 mm) [21]. Hence, state-
of-the-art MRI should be recommended [8].
The diagnostic performance of CT and MRI for evaluating
vascular invasion is still controversial. The best performance
was shown by MDCT in the past, but recent advances in MR
technology has made the diagnostic performance of MDCT
and MRI comparable (mean sensitivity, 80% vs. 65%; mean
specificity, 98% vs. 97%, respectively) for vascular infiltration
[22,23]. In our study, 6.0% of patients were reclassified from
potentially resectable state to unresectable state due to addi-
tional detection of major vascular invasion by MRI in addi-
tion to CT. This may be contrary to the findings of previous
studies demonstrating that CT was slightly better than or
similar to MRI in the assessment of vasculature invasion.
One reason for this discrepancy could be that most of the pre-
vious studies compared CT and MRI, but our study evalu-
ated the additional value of MRI after CT, as in routine
clinical practice.
In terms of overall and recurrence-free survival, there were
no significant differences between the CT only and CT+MR
groups in our study. This was a retrospective study, and
there are many unaccounted factors that affect the survival
in pancreatic cancer, that include not only disease factors but
also socioeconomic factors [24,25], and pre-treatment diag-
nostic imaging might not have direct effect on the survival.
In our study, other well-known factors did not show signif-
icant differences between the CT only and CT+MR groups
except that higher proportion of patients belonging to the CT
only group received the neoadjuvant therapy, and this might
affect the clinical outcome [3,24,26,27]. Within the CT+MR
group, patients with potentially resectable state had a higher
overall survival than patients with unresectable state, sug-
gesting that MRI allowed the clinicians to determine the most
appropriate treatment.
The major limitation of our study was that there were no
pre-defined criteria who should undergo additional MR 
imaging; this reflects the limitation in the current guideline
and is the background for our study. Before analysis, we 
hypothesized that patients with borderline resectable or 
indeterminate states on CT were more likely to undergo MRI
than patients with resectable state. However, there was no
significant difference in proportion of the patients undergo-
ing additional MRI among the three CT-based categories.
Second, the imaging technique used in this study was not
uniform. Some patients underwent single portal venous
phase CT not the dual phase pancreatic protocol CT, but
there were no significant differences in proportion of CT pro-
tocols between the CT only and CT+MR groups. In clinical
practice, some patients undergo single phase CT (routine CT
protocol) due to nonspecific symptoms, and we used it for
evaluation of pancreatic cancer staging without obtaining
dual phase CT because of radiation and reimbursement 
issues. Regarding MRI, some patients underwent MRI with-
out DWI using a general extracellular contrast agent instead
of the recently introduced hepatocyte-specific contrast agent.
A recent paper showed no difference between the two con-
trast agents in the evaluation of liver metastases from col-
orectal cancer [28]. This is beyond the scope of our study, and
a further study is needed. Finally, our study had the inherent
limitations of a retrospective study.
In conclusion, additional MRI resulted in changes of 
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resectability and treatment modification in a significant pro-
portion of patients who had potentially resectable state on
CT and delay in time to liver metastases in patients after cur-
ative surgery. Additional MRI to standard staging CT can be
recommended for surgical candidates of PDA.
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